✦ LIBER ✦

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis

✍ Scribed by Giancarlo Comi; Jeffrey A. Cohen; Douglas L. Arnold; Daniel Wynn; Massimo Filippi; for the FORTE Study Group

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 182 KB
Volume: 69
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.22316

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunological assay for assessing the ef

Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis

✍ Cinthia Farina; Stefan Wagenpfeil; Reinhard Hohlfeld 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 502 KB

A multicenter study of the predictors of

A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis

✍ Howard Zwibel; Gabriel Pardo; Shelly Smith; Douglas Denney; MerriKay Oleen-Burke 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 254 KB

European/Canadian multicenter, double-bl

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

✍ Giancarlo Comi; Massimo Filippi; Jerry S. Wolinsky 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 698 KB

## Abstract Two prior double‐blind, placebo‐controlled, randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS). This study was designed to determine the effect, onset, and durability of any effect of GA on dis

Guidelines for clinical trials of new th

Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Reporting extended results from phase III clinical trials

✍ D. E. Goodkin; S. Reingold; W. Sibley; J. Wolinsky; H. McFarland; D. Cookfair; F 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

Phase 2 study of high-dose proton therap

Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer

✍ Joe Y. Chang; Ritsuko Komaki; Charles Lu; Hong Y. Wen; Pamela K. Allen; Anne Tsa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 2 views

Phase III double-blind comparison of int

Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy

✍ George W. Sledge Jr.; Lawrence Einhorn; Catherine Nag; Karen House 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 508 KB

Background. Ondansetron hydrochloride is a selective serotonin subtype 3 (5HTJ receptor antagonist that has been shown to be an effective antiemetic in patients receiving cisplatin chemotherapy. Methods. This double-blind study compared the safety and efficacy of intravenous ondansetron with metocl